AU2018330423B2 - Vasopressin receptor antagonists and products and methods related thereto - Google Patents

Vasopressin receptor antagonists and products and methods related thereto Download PDF

Info

Publication number
AU2018330423B2
AU2018330423B2 AU2018330423A AU2018330423A AU2018330423B2 AU 2018330423 B2 AU2018330423 B2 AU 2018330423B2 AU 2018330423 A AU2018330423 A AU 2018330423A AU 2018330423 A AU2018330423 A AU 2018330423A AU 2018330423 B2 AU2018330423 B2 AU 2018330423B2
Authority
AU
Australia
Prior art keywords
independently
lower alkyl
halo
haloalkyl
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018330423A
Other languages
English (en)
Other versions
AU2018330423A1 (en
Inventor
Gary Brandt
Mark Chambers
David Hardick
Robert M. Jones
Chris KNIGHT
Chris Lock
Jason Tierney
Mariangela URBANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neumora Therapeutics Inc
Original Assignee
Neumora Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neumora Therapeutics Inc filed Critical Neumora Therapeutics Inc
Publication of AU2018330423A1 publication Critical patent/AU2018330423A1/en
Application granted granted Critical
Publication of AU2018330423B2 publication Critical patent/AU2018330423B2/en
Assigned to Neumora Therapeutics, Inc. reassignment Neumora Therapeutics, Inc. Request for Assignment Assignors: BLACKTHORN THERAPEUTICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2018330423A 2017-09-05 2018-09-05 Vasopressin receptor antagonists and products and methods related thereto Active AU2018330423B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554452P 2017-09-05 2017-09-05
US62/554,452 2017-09-05
PCT/US2018/049607 WO2019050988A1 (en) 2017-09-05 2018-09-05 ANTAGONISTS OF THE VASOPRESSIN RECEPTOR, PRODUCTS AND RELATED METHODS

Publications (2)

Publication Number Publication Date
AU2018330423A1 AU2018330423A1 (en) 2020-03-05
AU2018330423B2 true AU2018330423B2 (en) 2023-04-06

Family

ID=63708454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018330423A Active AU2018330423B2 (en) 2017-09-05 2018-09-05 Vasopressin receptor antagonists and products and methods related thereto

Country Status (13)

Country Link
US (2) US10538530B2 (https=)
EP (1) EP3679043B9 (https=)
JP (1) JP7368357B2 (https=)
KR (1) KR102765806B1 (https=)
CN (1) CN111212842B (https=)
AU (1) AU2018330423B2 (https=)
CA (1) CA3072766A1 (https=)
ES (1) ES2951874T3 (https=)
IL (1) IL272563B2 (https=)
MX (1) MX2020002436A (https=)
SG (1) SG11202001498QA (https=)
WO (1) WO2019050988A1 (https=)
ZA (2) ZA202001027B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CA3190277A1 (en) 2020-09-03 2022-03-10 Joerg Benz Heterocyclic compounds
CN117295726A (zh) * 2021-04-23 2023-12-26 豪夫迈·罗氏有限公司 杂环化合物
WO2023130050A1 (en) * 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
US20250170100A1 (en) * 2021-12-29 2025-05-29 Psy Therapeutics, Inc. Monoacylglycerol lipase inhibitors and use thereof for the treatment of anxiety and related conditions
CN120379996A (zh) * 2022-08-11 2025-07-25 瑞敏德股份有限公司 用于治疗神经退行性障碍的(氮杂)螺庚烷衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015173392A1 (en) * 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2025005A (en) * 1930-01-02 1935-12-17 Union Switch & Signal Co Multiple control apparatus
DE3930262A1 (de) * 1989-09-11 1991-03-21 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5091387A (en) * 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
HUP0203548A3 (en) * 1999-07-21 2003-04-28 Astrazeneca Ab New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
WO2006034015A1 (en) * 2004-09-17 2006-03-30 Osi Pharmaceuticals, Inc. (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors
KR100984893B1 (ko) * 2005-07-21 2010-10-01 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항제로서의인돌-3-일-카보닐-피페리딘-벤조이미다졸 유도체
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
DE602007006990D1 (de) 2006-12-07 2010-07-15 Hoffmann La Roche Spiropiperidinderivate als antagonisten des via-rezeptors
DE602007006989D1 (en) * 2006-12-07 2010-07-15 Hoffmann La Roche Spiropiperidinderivate
US8329904B2 (en) 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
WO2011036204A1 (en) * 2009-09-24 2011-03-31 Shire-Movetis N.V. [1,4]-benzodiazepines as vasopressin v2 receptor antagonists
CN105263910A (zh) 2013-02-18 2016-01-20 斯克利普斯研究所 具有治疗潜力的血管加压素受体调节剂
JP6502267B2 (ja) 2013-02-18 2019-04-17 スプリング バンク ファーマシューティカルズ，インコーポレイテッド ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計
US9688678B2 (en) * 2014-05-15 2017-06-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases
WO2018226769A1 (en) * 2017-06-05 2018-12-13 Blackthorn Therapeutics, Inc. 1-(2-azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives as v1a receptor antagonists for treating neuropsychological disorders
WO2020123872A1 (en) 2018-12-12 2020-06-18 Blackthorn Therapeutics, Inc. 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015173392A1 (en) * 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases

Also Published As

Publication number Publication date
ES2951874T3 (es) 2023-10-25
US12152038B2 (en) 2024-11-26
IL272563A (en) 2020-03-31
EP3679043B1 (en) 2023-05-31
ZA202104313B (en) 2024-12-18
IL272563B2 (en) 2023-02-01
IL272563B (en) 2022-10-01
EP3679043B9 (en) 2023-09-27
WO2019050988A1 (en) 2019-03-14
AU2018330423A1 (en) 2020-03-05
CN111212842B (zh) 2022-10-25
CN111212842A (zh) 2020-05-29
EP3679043A1 (en) 2020-07-15
KR102765806B1 (ko) 2025-02-10
KR20200051686A (ko) 2020-05-13
US20190169202A1 (en) 2019-06-06
US20210317126A1 (en) 2021-10-14
US10538530B2 (en) 2020-01-21
ZA202001027B (en) 2023-10-25
JP2020532592A (ja) 2020-11-12
JP7368357B2 (ja) 2023-10-24
MX2020002436A (es) 2020-07-13
NZ762031A (en) 2024-04-26
CA3072766A1 (en) 2019-03-14
SG11202001498QA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
AU2018330423B2 (en) Vasopressin receptor antagonists and products and methods related thereto
AU2019344897B2 (en) Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
TWI851451B (zh) 經取代之1,2-二氫-3H-吡唑并[3,4-d]嘧啶-3-酮
ES2987744T3 (es) Inhibidores de calicreína plasmática y usos de los mismos
US10787453B2 (en) Octahydropyrrolopyrroles their preparation and use
JP2023510929A (ja) ヘテロアリール誘導体、その製造方法およびその使用
AU2015253232B2 (en) Substituted 4-phenylpiperidines, their preparation and use
US20180237391A1 (en) Octahydrocyclopentapyrroles, their preparation and use
JP2021505598A (ja) 心不全およびそれに関連する障害の治療または予防に有用なβ−３アドレナリン受容体のモジュレーター
US20250230138A1 (en) Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications
JP2024505711A (ja) 窒素含有多環式縮合環系化合物、その医薬組成物、製造方法及び用途
RS65910B1 (sr) Heterociklično jedinjenje
US11858943B2 (en) Vasopressin receptor antagonists and products and methods related thereto
US12247037B2 (en) 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
HK40033061B (en) Vasopressin receptor antagonists and products and methods related thereto
HK40033061A (en) Vasopressin receptor antagonists and products and methods related thereto
US10774083B2 (en) Heterocyclic amide compound
WO2016171181A1 (ja) ２位置換縮合ピラゾール誘導体
US20240174663A1 (en) Pyrimidine or pyridine derivatives useful as hcn2 modulators
BR112019019157A2 (pt) antagonistas de receptor de capa-opiode e produtos e métodos relacionados aos mesmos

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEUMORA THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): BLACKTHORN THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)